Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration

BackgroundPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and despite low incidence rates, it remains the sixth leading cause of cancer related deaths worldwide. Immunotherapy, which aims to enhance the immune system’s ability to recognize and eliminate cancer cell...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vinicius Kannen, Marit Rasmussen, Siddhartha Das, Paolo Giuliana, Fauzia N. Izzati, Hani Choksi, Linnea A. M. Erlingsson, Ninni E. Olafsen, Samaneh S. Åhrling, Paola Cappello, Indrek Teino, Toivo Maimets, Kristaps Jaudzems, Antanas Gulbinas, Zilvinas Dambrauskas, Landon J. Edgar, Denis M. Grant, Jason Matthews
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Immunology
Subjects:	Poly-ADP-ribose polymerase 7 type I interferon pancreatic cancer CRISPR/Cas9 tumour infiltrating leukocytes
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1513595/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration

Similar Items